In fact, the percentage of LOH in Eμ-TCL1;p53R172H/+ leukemias was strikingly similar regardless of treatment status, suggesting ibrutinib does not promote a mutant p53-mediated escape mechanism. The gene discussed is TP53; the disease is leukemia.